Showing 1 to 2 of 2 results


China Approves Novel Influenza Drug Onradivir
China approved Onradivir, a novel influenza A treatment targeting the PB2 protein, offering faster symptom relief and lower resistance than existing drugs; it's administered as a 0.6-gram tablet three times daily for five days.
China Approves Novel Influenza Drug Onradivir
China approved Onradivir, a novel influenza A treatment targeting the PB2 protein, offering faster symptom relief and lower resistance than existing drugs; it's administered as a 0.6-gram tablet three times daily for five days.
Progress
48% Bias Score

China Approves Novel Influenza Drug Onradivir
China approved Onradivir, a novel influenza A treatment targeting the PB2 protein, offering faster symptom relief and lower resistance potential than existing drugs like oseltamivir and baloxavir marboxil, potentially reducing the global burden of influenza.

China Approves Novel Influenza Drug Onradivir
China approved Onradivir, a novel influenza A treatment targeting the PB2 protein, offering faster symptom relief and lower resistance potential than existing drugs like oseltamivir and baloxavir marboxil, potentially reducing the global burden of influenza.
Progress
48% Bias Score
Showing 1 to 2 of 2 results